Global Myasthenia Gravis Disease Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, End Use, and Region

Description

List of Tables

The myasthenia gravis disease market size is expected to reach USD 6.19 billion by 2034, according to a new study by Polaris Market Research. The report "Myasthenia Gravis Disease Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Thymectomy, Cholinesterase Inhibitors, and Rapid Immunotherapies), End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Myasthenia Gravis (MG) is a chronic autoimmune disorder that causes weakness in the skeletal muscles, particularly those responsible for controlling voluntary movements like eye muscles, facial muscles, and limbs. The condition occurs when the body's immune system produces antibodies that interfere with the communication between nerve cells and muscle cells, preventing the normal transmission of signals.

The myasthenia gravis disease market is driven by several factors, including the increasing global prevalence of the condition, advancements in diagnostic techniques, and the growing demand for more effective treatment options. The development and approval of biologic therapies, such as monoclonal antibodies and immunotherapies, are offering patients new ways to manage severe forms of the disease.

Additionally, the trend toward personalized medicine, which tailors treatments based on genetic and molecular profiles, is gaining traction. The myasthenia gravis disease market growth is also supported by rising patient awareness, the expansion of clinical trials, and improving healthcare access, particularly in emerging markets such as Asia Pacific. Opportunities lie in addressing the needs of refractory patients, improving treatment affordability, and expanding access to advanced therapies. Overall, the market is poised for steady growth as more effective and accessible treatment options continue to emerge.

Myasthenia Gravis Disease Market Report Highlights

Cholinesterase inhibitors dominate the myasthenia gravis market, serving as the primary treatment for most patients with mild to moderate symptoms. However, the segment of rapid immunotherapies, including IVIG and plasmapheresis, is registering the fastest growth due to increasing demand for advanced therapies in severe cases.

Hospitals hold the largest myasthenia gravis disease market share in the myasthenia gravis treatment market, as they provide comprehensive care for both acute exacerbations and severe MG cases. The clinic segment, however, is experiencing the fastest growth, driven by the increasing shift towards outpatient care and improved accessibility to specialized treatments.

North America dominates the myasthenia gravis market, owing to its advanced healthcare infrastructure, high awareness, and significant patient population. However, Asia Pacific is the fastest growing market, driven by expanding healthcare access, improving diagnostic capabilities, and increasing adoption of innovative therapies.

Polaris Market Research has segmented the myasthenia gravis disease market report based on treatment type, end-use, and region:

By Treatment Type Outlook (Revenue-USD Billion, 2020 - 2034)

Thymectomy
Cholinesterase Inhibitors
Rapid Immunotherapies

By End Use Outlook (Revenue-USD Billion, 2020 - 2034)

Hospitals
Clinics

By Regional Outlook (Revenue-USD Billion, 2020 - 2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM1546

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Myasthenia Gravis Disease Market Insights

4.1. Myasthenia Gravis Disease Market - Market Snapshot
4.2. Myasthenia Gravis Disease Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Increased Focus on Targeted Therapies
  - 4.2.1.2. Advancements in Immunotherapy
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Low Survival Rates
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Myasthenia Gravis Disease Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Myasthenia Gravis Disease Market, by Treatment Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
5.3. Thymectomy
- 5.3.1. Global Myasthenia Gravis Disease Market, by Thymectomy, by Region, 2020-2034 (USD Billion)
5.4. Cholinesterase Inhibitors
- 5.4.1. Global Myasthenia Gravis Disease Market, by Cholinesterase Inhibitors, by Region, 2020-2034 (USD Billion)
5.5. Rapid Immunotherapies
- 5.5.1. Global Myasthenia Gravis Disease Market, by Rapid Immunotherapies, by Region, 2020-2034 (USD Billion)

6. Global Myasthenia Gravis Disease Market, by End-use

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
6.3. Scientific Research
- 6.3.1. Global Myasthenia Gravis Disease Market, by Scientific Research, by Region, 2020-2034 (USD Billion)
6.4. Medicine and Vaccine R&D
- 6.4.1. Global Myasthenia Gravis Disease Market, by Medicine and Vaccine R&D, by Region, 2020-2034 (USD Billion)
6.5. Cloning Experiment
- 6.5.1. Global Myasthenia Gravis Disease Market, by Cloning Experiment, by Region, 2020-2034 (USD Billion)
6.6. Others
- 6.6.1. Global Myasthenia Gravis Disease Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Myasthenia Gravis Disease Market, by Geography

7.1. Key Findings
7.2. Introduction
- 7.2.1. Myasthenia Gravis Disease Market Assessment, By Geography, 2020-2034 (USD Billion)
7.3. Myasthenia Gravis Disease Market - North America
- 7.3.1. North America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.3.2. North America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.3.3. Myasthenia Gravis Disease Market - U.S.
  - 7.3.3.1. U.S.: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.3.3.2. U.S.: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.3.4. Myasthenia Gravis Disease Market - Canada
  - 7.3.4.1. Canada: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.3.4.2. Canada: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
7.4. Myasthenia Gravis Disease Market - Europe
- 7.4.1. Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.4.2. Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.3. Myasthenia Gravis Disease Market - UK
  - 7.4.3.1. UK: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.4.3.2. UK: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.4. Myasthenia Gravis Disease Market - France
  - 7.4.4.1. France: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.4.4.2. France: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.5. Myasthenia Gravis Disease Market - Germany
  - 7.4.5.1. Germany: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.4.5.2. Germany: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.6. Myasthenia Gravis Disease Market - Italy
  - 7.4.6.1. Italy: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.4.6.2. Italy: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.7. Myasthenia Gravis Disease Market - Spain
  - 7.4.7.1. Spain: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.4.7.2. Spain: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.8. Myasthenia Gravis Disease Market - Netherlands
  - 7.4.8.1. Netherlands: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.4.8.2. Netherlands: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.9. Myasthenia Gravis Disease Market - Russia
  - 7.4.9.1. Russia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.4.9.2. Russia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.10. Myasthenia Gravis Disease Market - Rest of Europe
  - 7.4.10.1. Rest of Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.4.10.2. Rest of Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
7.5. Myasthenia Gravis Disease Market - Asia Pacific
- 7.5.1. Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.5.2. Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.3. Myasthenia Gravis Disease Market - China
  - 7.5.3.1. China: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.5.3.2. China: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.4. Myasthenia Gravis Disease Market - India
  - 7.5.4.1. India: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.5.4.2. India: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.5. Myasthenia Gravis Disease Market - Malaysia
  - 7.5.5.1. Malaysia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.5.5.2. Malaysia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.6. Myasthenia Gravis Disease Market - Japan
  - 7.5.6.1. Japan: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.5.6.2. Japan: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.7. Myasthenia Gravis Disease Market - Indonesia
  - 7.5.7.1. Indonesia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.5.7.2. Indonesia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.8. Myasthenia Gravis Disease Market - South Korea
  - 7.5.8.1. South Korea: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.5.8.2. South Korea: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.9. Myasthenia Gravis Disease Market - Australia
  - 7.5.9.1. Australia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.5.9.2. Australia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.10. Myasthenia Gravis Disease Market - Rest of Asia Pacific
  - 7.5.10.1. Rest of Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.5.10.2. Rest of Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
7.6. Myasthenia Gravis Disease Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.6.2. Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.6.3. Myasthenia Gravis Disease Market - Saudi Arabia
  - 7.6.3.1. Saudi Arabia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.6.3.2. Saudi Arabia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.6.4. Myasthenia Gravis Disease Market - UAE
  - 7.6.4.1. UAE: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.6.4.2. UAE: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.6.5. Myasthenia Gravis Disease Market - Israel
  - 7.6.5.1. Israel: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.6.5.2. Israel: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.6.6. Myasthenia Gravis Disease Market - South Africa
  - 7.6.6.1. South Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.6.6.2. South Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.6.7. Myasthenia Gravis Disease Market - Rest of Middle East & Africa
  - 7.6.7.1. Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.6.7.2. Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
7.7. Myasthenia Gravis Disease Market - Latin America
- 7.7.1. Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.7.2. Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.7.3. Myasthenia Gravis Disease Market - Mexico
  - 7.7.3.1. Mexico: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.7.3.2. Mexico: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.7.4. Myasthenia Gravis Disease Market - Brazil
  - 7.7.4.1. Brazil: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.7.4.2. Brazil: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.7.5. Myasthenia Gravis Disease Market - Argentina
  - 7.7.5.1. Argentina: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.7.5.2. Argentina: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.7.6. Myasthenia Gravis Disease Market - Rest of Latin America
  - 7.7.6.1. Rest of Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  - 7.7.6.2. Rest of Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Alexion Pharmaceuticals (AstraZeneca)
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Mitsubishi Tanabe Pharma
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Bristol Myers Squibb
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Grifols
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Baxter International
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. CSL Behring
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. UCB
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. Prothena Biosciences
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Argenx
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Sanofi
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
9.11. Amgen
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
9.12. AbbVie
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development
9.13. Pfizer
- 9.13.1. Company Overview
- 9.13.2. Financial Performance
- 9.13.3. Product Benchmarking
- 9.13.4. Recent Development
9.14. Roche
- 9.14.1. Company Overview
- 9.14.2. Financial Performance
- 9.14.3. Product Benchmarking
- 9.14.4. Recent Development
9.15. Novartis
- 9.15.1. Company Overview
- 9.15.2. Financial Performance
- 9.15.3. Product Benchmarking
- 9.15.4. Recent Development